- Home
- ADXN vs OGEN Comparison
ADXN vs OGEN Comparison
Compare ADXN & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | OGEN |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 3.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADXN | OGEN |
|---|---|---|
| Price | $7.99 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1K | ★ 88.4K |
| Earning Date | 12-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,824.00 | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $0.82 |
| 52 Week High | $12.05 | $18.90 |
Technical Indicators
Market Signals| Indicator | ADXN | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 40.98 |
| Support Level | $7.48 | $0.82 |
| Resistance Level | $8.90 | $0.89 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 51.85 | 20.00 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.